domingo, 22 de noviembre de 2026
Cancer Drug Approval Standards Face New Scrutiny Nov 20, 2026
https://www.medscape.com/for-you?hpid=7&ecd=mkm_ret_261122_mscpmrk_onc_perspectives_clihub_etid8923416&uac=148436CN&impID=8923416
Cancer drug access decisions increasingly affect oncology practice after trials meet endpoints but before long-term benefit is fully defined. Most evidence here comes from European and North American policy discussions, yet the approval and access questions map directly to United States cancer care and formulary use.
Suscribirse a:
Enviar comentarios (Atom)


No hay comentarios:
Publicar un comentario